AACR Annual Meeting 2025
April 25-30, 2025 | Chicago, IL | The critical driver of progress against cancer, where the cancer community shares the latest breakthroughs.
Related Articles
Daily Takeaways From the AACR Annual Meeting 2025: Sunday, April 27
Takeaways from day three of the AACR Annual Meeting 2025 included the Opening Ceremony, a panel on cancer research at a crossroads, and more.
Off-the-shelf CAR Natural Killer Cell Therapy with Logic Gates Elicits Complete Remissions in Relapsed or Refractory Blood Cancers
Several patients with AML, who were treated with SENTI-202 experienced a complete remission after not responding to or having relapsed following prior treatments, according to…
Pretrained Machine Learning Models May Help Accurately Diagnose Nonmelanoma Skin Cancer in Resource-limited Settings
AI models, pretrained on vast datasets, significantly outperformed a standard baseline model in identifying nonmelanoma skin cancers from digital images of tissue samples, according to…
AI-driven Biomarker Model May Improve Detection of Cancer Cachexia
A multimodal, AI-driven model that analyzes routinely collected imaging and clinical information led to more accurate prediction of cancer cachexia than standard methods, according to…
Adjuvant PD-1 Blockade for Mismatch Repair-deficient Solid Cancers Directed by ctDNA Status Delivers Clinical Benefit
Pembrolizumab cleared minimal residual disease and protected against recurrence in patients with DNA mismatch repair-deficient early-stage solid cancers who had detectable circulating tumor DNA after…
Neoadjuvant PD-1 Blockade in Early-stage Mismatch Repair-deficient Cancers Can Eliminate the Need for Surgery Regardless of Tumor Type
PD-1 immunotherapy can eliminate the need for surgery in patients with early-stage, DNA mismatch repair-deficient solid cancers, according to results presented at the AACR Annual…
Adding Perioperative Pembrolizumab to Standard of Care Improves Outcomes in Patients With Newly Diagnosed Head and Neck Cancer
Supplementing standard therapy with perioperative PD-1 blockade benefitted patients with untreated, locally advanced head and neck cancer in a phase III clinical trial, according to…
Oral Investigational Agent Zoldonrasib Elicits Objective Responses in Patients With KRAS G12D-mutated Lung Cancer
The KRAS G12D inhibitor zoldonrasib elicited responses in patients with KRAS G12D-mutated non-small cell lung cancer in a phase I clinical trial, according to results…
2025 AACR Advocacy Pavilion
Discover the list of exhibitors participating in the 2025 Advocacy Partners Pavilion at the AACR Annual Meeting.
AACR Announces Recipients of the 2025 AACR June L. Biedler Prize for Cancer Journalism
The AACR is pleased to announce the recipients of the 2025 AACR June L. Biedler Prize for Cancer Journalism.